Modulating the immune system: a vaccine for glaucoma?
Glaucomatous neuropathy, like other neurodegenerative diseases, is a multi-dimensional disease in which various molecular and cellular factors contribute to the pathological process. These factors, while not initially causative, are key elements in disease progression and may continue to contribute even after the primary pathology is alleviated. An entire field of research of neuroprotection and restoration has opened up as part of the search for additional ways of slowing disease progression. We have proposed, on the basis of experimental evidence, that a vaccine could be a means of recruiting the immune system to help eliminate many of the factors associated with glaucomatous neurodegeneration and thus prevent disease progression, though not its onset. This immune defence involves lymphocytes, resident and infiltrating innate immune cells, the microglia, and macrophages. The antigens of choice are synthetic antigens, such as glatiramer acetate, that weakly cross-react with self-antigens in the retina and optic nerves. The vaccine induces a beneficial immune response that recruits immune effector cells to counteract or neutralize many of the compounds and factors that contribute to ongoing destruction, and in addition supports cell renewal and repair.
Schwartz
Michal
M
Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel. Michal.Schwartz@weizmann.ac.il
D005901:Glaucoma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007107:Immune System / Q000502:physiology*; D016233:Immunotherapy, Active; D009901:Optic Nerve Diseases / Q000276:immunology / Q000628:therapy*